Holen Sie sich die Stockscreener-App
3.27
0.62%
0.02
Schlusskurs vom Vortag:
$3.25
Offen:
$3.25
24-Stunden-Volumen:
238.60K
Relative Volume:
0.20
Marktkapitalisierung:
$117.96M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-1.7302
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
-4.66%
1M Leistung:
-26.02%
6M Leistung:
+81.67%
1J Leistung:
+200.00%
1-Tages-Spanne:
$3.25
$3.425
1-Wochen-Bereich:
$3.24
$3.6175
52-Wochen-Spanne:
$1.00
$4.60
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Vergleichen Sie IMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
3.278 | 126.67M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.26 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.94 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
439.38 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
638.16 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.40 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Eingeleitet | Needham | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Eingeleitet | Mizuho | Neutral |
| 2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Using Python tools to backtest Immuneering Corporation strategiesFree Daily Volume Spike Trading Signals - Newser
Should you hold or exit Immuneering Corporation nowFree Investment Plan With Growth Optimization - Newser
Is Immuneering Corporation showing signs of accumulationFree Trend Analysis for Safer Trades - Newser
Applying chart zones and confluence areas to Immuneering CorporationFree Trade Setups With Clear Risk Limits - Newser
Is Immuneering Corporation stock entering bullish territoryAI Volatility Forecast and Risk Monitor - Newser
Is this a good reentry point in Immuneering CorporationIntraday Movement Recap and Chart Summary - Newser
Quant Tools Rank Immuneering Corporation as High Risk High RewardStep-by-Step Trade Signal Implementation Guide Ready - metal.it
Is it the right time to buy Immuneering Corporation stockExtraordinary earning power - Jammu Links News
What drives Immuneering Corporation stock priceGet high-impact stock recommendations now - Jammu Links News
How many analysts rate Immuneering Corporation as a “Buy”Build a diversified portfolio for maximum returns - Jammu Links News
What are Immuneering Corporation company’s key revenue driversExceptional stock performance - Jammu Links News
Multi asset correlation models including Immuneering CorporationFree Multi-Bagger Potential Stock Forecast Tools - Newser
How does Immuneering Corporation compare to its industry peersStock Strategy Entry Points Backed By Experts - Jammu Links News
Real time breakdown of Immuneering Corporation stock performanceStrong Buy Opportunity with Volume Support - Newser
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
How Efficient Is Immuneering Corporation at Controlling Operating CostsFree Trade Timing Strategy With Technical Data - Newser
Immuneering Corporation’s Price Action Aligns with Quant SignalsConsistent Income Focused Trade List Analyzed - metal.it
Published on: 2025-07-28 06:27:12 - Jammu Links News
What makes Immuneering Corporation stock price move sharplyProven High Yield Signals - metal.it
How strong is Immuneering Corporation company’s balance sheetBreakout profit opportunities - Jammu Links News
What analysts say about Immuneering Corporation stockAccelerated wealth expansion - PrintWeekIndia
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World
Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com
Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser
Immuneering Corporation Rings the Closing Bell - Nasdaq
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan
Immuneering Corporation shares rise 10.63% intraday after receiving U.S. composition of matter patent for atebimetinib. - AInvest
The MEK effect on cancer — a slow and steady approach to drug resistance - PharmaVoice
Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa
Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com
Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus
Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest
At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - stocksregister.com
Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com
Insider Buying: Brett Hall Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com
Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com
Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients - Pipelinereview
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immuneering Corp-Aktie (IMRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HAUSMAN DIANA | Director |
Jul 02 '25 |
Buy |
3.60 |
2,500 |
8,989 |
2,500 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jul 02 '25 |
Buy |
3.57 |
700 |
2,499 |
10,729 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jul 02 '25 |
Buy |
3.53 |
7,015 |
24,792 |
2,312,852 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jul 01 '25 |
Buy |
3.38 |
2,985 |
10,087 |
2,305,837 |
| Schall Thomas J. | Director |
Jun 27 '25 |
Buy |
3.66 |
9,500 |
34,788 |
52,885 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 20 '25 |
Buy |
2.70 |
7,415 |
20,020 |
353,311 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 23 '25 |
Buy |
2.43 |
6,007 |
14,596 |
359,318 |
| Brakewood Harold Eugene | Chief Business Officer |
Jun 20 '25 |
Buy |
2.53 |
1,900 |
4,804 |
5,800 |
| Feinberg Peter | Director |
Jun 18 '25 |
Buy |
2.53 |
25,000 |
63,188 |
136,766 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jun 18 '25 |
Buy |
2.39 |
21,000 |
50,144 |
2,302,852 |
3.57%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):